Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. on March 21, 2017. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.

Material Changes

  • Board Expansion: The Board of Directors voted to increase the number of directors from seven to eight.
  • New Appointment: Howard D. Palefksy was elected to serve as a director.
  • Compensation Arrangement: Mr. Palefksy was awarded an option to purchase 28,571 shares of common stock, exercisable over four years. He is also eligible for the standard non-employee director compensation program, which includes a $20,000 annual retainer and potential committee fees ranging from $10,000 to $30,000 depending on role.

Guidance, Outlook, and Risks

The filing does not contain guidance, outlook, management commentary on operations, or specific risk factors. It notes that Mr. Palefksy is anticipated to enter into the Company's standard indemnification agreement for directors. A press release announcing the appointment was issued on March 23, 2017.

Investor Verification Checklist

  • Verify the total number of directors on the Board following the expansion to eight.
  • Confirm the vesting schedule and terms of the 28,571 stock options granted to Mr. Palefksy.
  • Review the Company's standard non-employee director compensation policy for details on committee assignments and fees.
  • Check for any subsequent filings regarding Mr. Palefksy's committee assignments, as none were named at the time of this report.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.